CTKBCytek Biosciences, Inc.

$553M

Q4 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$39M+27.0% YoY

Gross Profit

$24M60.8% margin

Operating Income

$1M3.4% margin

Net Income

-$1M-3.1% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

+13.1%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$4M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$463M

Total Liabilities

$58M

Stockholders' Equity

$405M

Cash & Equivalents

$365M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$31M	+27.0%
Gross Profit	$24M	$19M	+21.5%
Operating Income	$1M	$8M	-83.3%
Net Income	-$1M	$6M	-121.3%

Revenue Segments

Product

$36M92%

Service

$3M8%

Geographic Segments

UNITED STATES

$18M47%

EMEA

$13M35%

Asia Pacific

$7M17%

Other

$633,0002%

CTKB Q4 2021 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena